Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes

by Blonde, Lawrence, Pencek, Richard, MacConell, Leigh
Published 2015

Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinica...

by MacConell, Leigh, Brown, Carl, Gurney, Kate, Han, Jenny
Published 2012

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years

by MacConell, Leigh, Pencek, Richard, Li, Yan, Maggs, David, Porter, Lisa
Published 2013

Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients

by MacConell, Leigh, Gurney, Kate, Malloy, Jaret, Zhou, Ming, Kolterman, Orville
Published 2015

Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks

by Diamant, Michaela, Van Gaal, Luc, Stranks, Stephen, Guerci, Bruno, MacConell, Leigh, Haber, Harry, Scism-Bacon, Jamie, Trautmann, Michael
Published 2012

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes

by Rosenstock, Julio, Shenouda, Sylvia K., Bergenstal, Richard M., Buse, John B., Glass, Leonard C., Heilmann, Cory R., Kwan, Anita Y.M., MacConell, Leigh A., Hoogwerf, Byron James
Published 2012

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects

by Darpö, Börje, Sager, Philip, MacConell, Leigh, Cirincione, Brenda, Mitchell, Malcolm, Han, Jenny, Huang, Wenying, Malloy, Jaret, Schulteis, Christine, Shen, Larry, Porter, Lisa
Published 2013